Huamei Pharmaceutical
Huamei Pharmaceutical is committed to becoming a leading pharmaceutical enterprise in the province that specializes in innovative traditional Chinese medicine products and embraces the broader health-care concept. The project covers an area of 46.3 mu and features a total construction area of approximately 38,300 square meters. It integrates production, R&D, and office functions in a scientifically and rationally planned layout. The facility includes core production areas such as a pre-processing workshop, a comprehensive formulation workshop, and an extraction workshop, as well as supporting buildings like a multi-functional office building and a wastewater treatment plant, laying a solid foundation for the company’s operations and sustainable development.
In terms of production capacity, Huamei Pharmaceutical boasts strong capabilities, operating eight production lines for various Chinese medicine dosage forms and thus achieving a substantial production scale. The company can extract 3,000 tons of Chinese medicinal materials annually, with an annual output of 4 billion Chinese medicine tablets, 1 billion hard capsules, 200 million granules, 10 million bottles of syrup, 30 million vials of compound preparations, and 1,000 tons of pills. Additionally, its annual production capacity for soft capsules and drop pills each reaches 10 million boxes, enabling it to meet the diverse demands of the market.
Enterprises adhere to innovation-driven development and deeply implement new industrial concepts. In equipment selection, they rigorously follow process requirements and GMP standards, choosing advanced pharmaceutical equipment both domestically and internationally to ensure technology that is energy-efficient and environmentally friendly. Leveraging MES systems, they are transforming their manufacturing platforms into smart ones, automatically generating big-data models tailored to specific processes and product characteristics to optimize production workflows. By deploying sensors or RFID systems, they achieve intelligent and automated control over the production process. The inspection systems feature automatic visual recognition capabilities, combined with line visualization and error-proofing alerts, thus creating a smart production environment that truly realizes unmanned workshops, intelligent interconnected control, and machine substitution—hallmarks of the industry’s cutting-edge production standards.
In terms of products, Huamei Pharmaceutical enjoys significant advantages. The market for Chitong Xiaoyanling Granules and Shenjin Huoluo Pills is highly scarce—only two companies currently produce these products. Although competing manufacturers already hold over 55% of the market share, thanks to their superior product quality and strong operational capabilities, these products still have enormous market potential. Furthermore, Baikejing Syrup and Tongguan Teng Oral Liquid are produced by only a few manufacturers, yet their sales have been growing at an annual rate exceeding 50%, demonstrating rapid growth momentum. In addition, the company is actively expanding its product pipeline to include classic renowned formulas, products with identical names and formulations, and formulated granules, introducing a series of highly competitive products that continuously fuel the company’s sustainable development.
Relying on its comprehensive sales network, Huamei Pharmaceutical can integrate resources across all channels—including distribution, controlled sales, medical investment promotion, and OEM/ODM investment promotion—ensuring that its products can be swiftly introduced into markets nationwide. This enables the company to achieve rapid production and immediate sales, effectively bridging the gap between manufacturing and the market and providing robust market support for its business development. Looking ahead, Huamei Pharmaceutical will continue to deepen its focus on the traditional Chinese medicine and greater health sector, driving forward with innovation as its engine and quality as its foundation, steadily advancing toward even higher goals.
Investment Hotline： +86-4001336009
Drug Vigilance Department Contact Hotline：
Address：Xinxiang South Railway Station, Xinxiang City, Henan Province
E-mail：zhongjieyaoye@126.com
Official WeChat
Official Douyin
Copyright © Henan Zhongjie Pharmaceutical Co., Ltd.
Privacy Agreement Supports IPV6 SEO